Hedley D W, Maroun J A, Espir M L
Postgrad Med J. 1975 Sep;51(599):615-8. doi: 10.1136/pgmj.51.599.615.
The effect of baclofen on spasticity and muscle spasms was assessed in thirty-five patients with multiple sclerosis. Benefit from reduction of spasticity was obtained in sixteen patients. A higher proportion of patients confined to a wheelchair was helped than ambulant patients, but overall functional improvement was limited. Twenty-one of the thirty-five patients had troublesome spasms and thirteen of them had significant relief on baclofen. Substituting identical dummy tablets confirmed that benefit was attributable to the pharmacological effects of baclofen in ten of the sixteen patients whose spasticity was reduced and in eight of the thirteen whose muscle spasms were relieved. In two of the remainder, benefit appeared to be due to placebo effect, and the others maintained their improvement after stopping the drug. The drug had to be withdrawn in nine patients because of increased weakness and in ten other patients who had intolerable side effects. The optimum dose of baclofen tolerated ranged from 15 mg to 80 mg daily. The importance of adjusting the dose regime to the requirement of each individual and starting with small doses in multiple sclerosis is emphasized.
在35例多发性硬化症患者中评估了巴氯芬对痉挛和肌肉痉挛的疗效。16例患者痉挛减轻，从中获益。与能行走的患者相比，更多轮椅受限患者得到了帮助，但总体功能改善有限。35例患者中有21例有令人烦恼的痉挛，其中13例在使用巴氯芬后痉挛明显缓解。用相同的安慰剂替代证实，在痉挛减轻的16例患者中有10例、肌肉痉挛缓解的13例患者中有8例，其获益归因于巴氯芬的药理作用。其余患者中有2例获益似乎是由于安慰剂效应，其他患者在停药后仍保持改善。9例患者因肌无力加重停药，另有10例患者有无法耐受的副作用而停药。巴氯芬的最佳耐受剂量为每日15毫克至80毫克。强调了在多发性硬化症中根据个体需求调整剂量方案并从小剂量开始的重要性。
